Moleculin Biotech, Inc. (Nasdaq: MBRX) announced its financial results for the year ended December 31, 2025, alongside significant operational updates. The company reported a decrease in research and development expenses to $15.9 million from $17.7 million in 2024, attributed to reduced sponsored research activities. General and administrative expenses rose slightly to $9.2 million, reflecting increased regulatory and legal services. As of December 31, 2025, Moleculin had cash and cash equivalents of $8.9 million, which, along with additional financing received in early 2026, is expected to support operations into the third quarter of 2026.

A pivotal highlight from the report is the ongoing MIRACLE trial, which evaluates Annamycin in combination with cytarabine for treating adult patients with relapsed or refractory acute myeloid leukemia (AML). The trial is on track for an interim data unblinding of 45 patients expected in mid-2026. Preliminary results from the first 30 patients indicate a promising 40% complete remission composite rate, suggesting that Annamycin may significantly improve treatment outcomes for this challenging patient population.

Moleculin's Chairman and CEO, Walter Klemp, expressed optimism about the trial's progress, emphasizing the potential of Annamycin as a significant advancement in AML therapy. The company is also expanding its research collaborations, including a new partnership focused on glioblastoma multiforme and positive results from a Phase 1 clinical trial of WP1066 in pediatric brain tumors. These developments position Moleculin for a potentially transformative year ahead as it navigates critical milestones in its clinical programs.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.